<DOC>
	<DOCNO>NCT00382239</DOCNO>
	<brief_summary>This study examine response several dos LY2148568 ( exenatide ) ass effect glucose control safety tolerability Japanese patient type 2 diabetes .</brief_summary>
	<brief_title>A Study Assess Effect Glucose Control Safety Tolerability LY2148568 In Japanese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed type 2 diabetes . Have body weight &gt; =50 kg . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Have participate study previously , study use exenatide GLP1 analog . Are treat exogenous insulin within 3 month screen . Are continuously treat follow excluded medication within 3 month screen ( 7 day per 1 month ) : *drugs directly affect gastrointestinal motility , include Nauzelin® ( domperidone ) , Primperan®/Terperan® ( metoclopramide ) , Ganaton® ( itopride ) , Acenalin® ( cisapride ) , Gasmotin® ( mosapride ) , Cerekinon® ( trimebutine ) . Have characteristic contraindicate concomitant medication , accord productspecific label . Have severe allergy hypersensitivity drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>LY2148568</keyword>
	<keyword>Lilly</keyword>
	<keyword>Amylin</keyword>
	<keyword>Japan</keyword>
</DOC>